Overview
NICE was unable to make recommendations on eltrombopag (Revolade) for severe aplastic anaemia refractory to immunosuppressive therapy because no evidence submission was received from Novartis.
Last reviewed: 27 January 2016
Next review: We will review this decision if the company decides to make a submission